Working… Menu
Trial record 33 of 232 for:    yeast

Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00479947
Recruitment Status : Unknown
Verified May 2007 by Faith Mediplex.
Recruitment status was:  Recruiting
First Posted : May 30, 2007
Last Update Posted : May 30, 2007
Chr Hansen
Information provided by:
Faith Mediplex

Brief Summary:
Yeast vaginitis is a very common ailment affecting premenopausal women in Nigeria. This condition is more prevalent in the age group between 21-30 years. More than 75% of premenopausal women and university students are diagnosed with yeast infections annually. In most of these women, recurrent rate of vaginal candidiasis with empiric therapy, stands between 70 and 80%. In addition, resistance to anti-fungal agents is increasing at an alarming speed, particularly with species other than Candida albicans such as C tropicalis and C glabrata. The healthy vaginal environment is composed mainly of lactobacilli and when these organisms are suppressed overgrowth of a large number of pathogens occur including yeasts. In this pilot study,we hypothesize that oral administration of two well documented strains of lactobacilli (L.rhamnosis GR-1 and L.reuteri RC-14 ) given to women with recurrent yeast vaginitis, following standard therapy with fluconazole will result in a significant reduction in recurrence rate of the disease.

Condition or disease Intervention/treatment Phase
Vaginal Candidiasis Drug: Probiotics (Natural product) Drug: Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14) Phase 1

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: A Double-Blind,Randomized Placebo-Controlled Study Using Probiotic Lactobacillus GR-1 and RC-14 as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis
Study Start Date : May 2007
Estimated Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Fluconazole

Primary Outcome Measures :
  1. In the placebo group of patients, it is anticipated that at the 3 month period, a recurrence rate of 50% will occur, whereas, in the treatment arm a reduction in recurrence to 25% will be achieved [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. Reduction in clinic visits for urogenital care and cost savings [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Premenopausal women suffering from acute or chronic yeast vaginitis and a past history of 3 or 4 episodes over the 12 months will be selected.
  • All participants must be symptomatic, i.e. the participant must have identified herself as suffering from one or more of the following: abnormal/odourless vaginal discharge, dyspareunia or dysuria, localized irritation or discomfort around the vagina.

Exclusion Criteria:

  • Participants must not be suffering from other urogenital infections or conditions such as HIV that will potentially alter their response to disease. Participants will be tested and excluded for the presence of Trichomonas vaginalis and Bacterial vaginosis at inclusion. Other conditions will be ruled out on the basis of medical history and clinical assessment.
  • Participants must not be pregnant.
  • Participants must not be younger than 18 or older than 50 years.
  • Participants must not be menstruating during diagnosis or treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00479947

Layout table for location contacts
Contact: Martin U Duru, MSc 234+8056650828
Contact: Kingsley C Anukam, PhD, MHPM 519-646-6000 ext 61547

Layout table for location information
FaithMediplex Recruiting
Benin, Edo, Nigeria
Principal Investigator: Chinonye C EZE-OKOROIKPA, MBBS         
Sub-Investigator: ALFRED AIYEBELEHIN, MBBS         
Sub-Investigator: Martin U Duru, MSc         
Sponsors and Collaborators
Faith Mediplex
Chr Hansen
Layout table for investigator information
Study Chair: Chinonye C EZE-OKOROIKPA, MBBS Faith Mediplex
Study Director: MARTIN U DURU, MSc Faith Mediplex
Principal Investigator: KINGSLEY C ANUKAM, PhD Benson Idahosa University, Benin City and Canadian R & D Centre for Probiotics, Lawson Health Research Intsitute, London, Ontario, Canada.
Study Chair: ALFRED AIYEBELEHIN, MBBS Faith Mediplex

Layout table for additonal information Identifier: NCT00479947     History of Changes
Other Study ID Numbers: UB-CHr-N
First Posted: May 30, 2007    Key Record Dates
Last Update Posted: May 30, 2007
Last Verified: May 2007
Keywords provided by Faith Mediplex:
Yeast vaginitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Candidiasis, Vulvovaginal
Vaginal Diseases
Genital Diseases, Female
Vulvar Diseases
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 CYP2C19 Inhibitors